Annexon (ANNX) Competitors $2.47 -0.23 (-8.52%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$2.56 +0.09 (+3.64%) As of 03/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. CALT, AUPH, GYRE, SNDX, ADPT, SYRE, SPRY, NRIX, ELVN, and NTLAShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Gyre Therapeutics Syndax Pharmaceuticals Adaptive Biotechnologies Spyre Therapeutics ARS Pharmaceuticals Nurix Therapeutics Enliven Therapeutics Intellia Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Do analysts prefer CALT or ANNX? Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, indicating a potential downside of 1.88%. Annexon has a consensus price target of $15.80, indicating a potential upside of 539.68%. Given Annexon's stronger consensus rating and higher possible upside, analysts clearly believe Annexon is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CALT or ANNX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 12.7% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer CALT or ANNX? In the previous week, Annexon had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Annexon and 0 mentions for Calliditas Therapeutics AB (publ). Annexon's average media sentiment score of 0.94 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Annexon is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Annexon Positive Which has more risk and volatility, CALT or ANNX? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Which has preferable valuation & earnings, CALT or ANNX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Annexon. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62AnnexonN/AN/A-$134.24M-$1.02-2.42 Does the MarketBeat Community prefer CALT or ANNX? Annexon received 28 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 77.46% of users gave Annexon an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% AnnexonOutperform Votes5577.46% Underperform Votes1622.54% Is CALT or ANNX more profitable? Annexon has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Annexon's return on equity of -38.99% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Annexon N/A -38.99%-33.90% SummaryAnnexon beats Calliditas Therapeutics AB (publ) on 12 of the 17 factors compared between the two stocks. Remove Ads Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$270.98M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-2.357.2324.5519.25Price / SalesN/A232.30396.2294.31Price / CashN/A65.6738.1634.64Price / Book0.776.617.064.46Net Income-$134.24M$142.13M$3.19B$247.07M7 Day Performance-1.20%1.72%0.18%1.77%1 Month Performance-5.00%2.31%5.53%-3.31%1 Year Performance-64.10%-5.07%14.21%5.26% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon1.6789 of 5 stars$2.47-8.5%$15.80+539.7%-62.8%$270.98MN/A-2.3560CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.6729 of 5 stars$8.40+2.9%$11.50+36.9%+73.7%$1.15B$235.13M-56.00300Positive NewsGYREGyre Therapeutics0.188 of 5 stars$12.28+1.4%N/A-41.3%$1.15B$105.03M0.0040SNDXSyndax Pharmaceuticals3.7151 of 5 stars$13.04+0.7%$36.00+176.1%-40.1%$1.12B$23.68M-3.59110Positive NewsADPTAdaptive Biotechnologies3.4601 of 5 stars$7.54+3.6%$9.10+20.7%+169.9%$1.12B$178.96M-6.92790SYRESpyre Therapeutics1.8644 of 5 stars$18.54+2.8%$54.83+195.8%-52.8%$1.12B$890,000.00-2.48100SPRYARS Pharmaceuticals3.3572 of 5 stars$11.44-3.6%$31.00+171.0%+44.0%$1.11B$2.57M-22.4390Earnings ReportAnalyst RevisionNRIXNurix Therapeutics2.0408 of 5 stars$13.93+2.5%$30.88+121.7%-7.0%$1.06B$54.55M-4.82300ELVNEnliven Therapeutics2.8775 of 5 stars$21.04+1.4%$38.25+81.8%+19.9%$1.03BN/A-11.0750NTLAIntellia Therapeutics4.4718 of 5 stars$9.58+4.8%$37.56+292.0%-67.5%$991.69M$57.88M-1.76600Analyst Revision Remove Ads Related Companies and Tools Related Companies CALT Competitors AUPH Competitors GYRE Competitors SNDX Competitors ADPT Competitors SYRE Competitors SPRY Competitors NRIX Competitors ELVN Competitors NTLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
